Chylocure

Chylocure is an Israeli biotechnology company developing a proprietary drug delivery platform that utilizes synthetic chylomicrons to transport therapeutic agents. The technology mimics the natural dietary lipid absorption pathway, allowing for the targeted delivery of hydrophobic small molecules and nucleic acids to specific organs, primarily the liver. By bypassing traditional systemic circulation hurdles, the platform aims to enhance the efficacy and reduce the toxicity of potent drugs. Chylocure's current pipeline focuses on treating hepatocellular carcinoma and various metabolic disorders. The company was founded based on research from the Hebrew University of Jerusalem and is supported by specialized life science investors.